aXichem and Chr. Olesen Set to Revolutionize Brazil’s Poultry and Swine Industries with aXiphen Launch at Nucleovet and SIAVS

MALMÖ, Sweden, March 19, 2024 /PRNewswire/ — aXichem AB (publ) (aXichem), the developer of innovative natural analogue feed additives, and Chr. Olesen, the renowned distributor, are delighted to announce the strategic launch of aXiphen in Brazil, set against the backdrop of two premier industry events: Nucleovet and the South American International Poultry and Swine Show (SIAVS). This launch is supported by a PR campaign aimed at maximizing the product’s introduction to the Brazilian market.

Nucleovet 9-11 of April, an esteemed symposium dedicated to advancing veterinary medicine and animal production, will serve as the initial stage for aXiphen’s introduction. Following Nucleovet, aXiphen will be featured at SIAVS, recognized as the largest and most influential event for the poultry and swine sectors in Brazil. SIAVS is scheduled to take place from August 6th to 8th, 2024, at Anhembi Parque, São Paulo, promising unparalleled exposure and engagement opportunities with key industry players.

This collaborative effort between aXichem and Chr. Olesen comes at a crucial time as Brazilian authorities heighten their focus on Salmonella control in export production, emphasizing the need for innovative solutions like aXiphen. Demonstrating remarkable efficacy in inhibiting Salmonella through methodologies that mirror Brazilian testing standards, aXiphen is ready to make a significant impact on the animal health and safety of Brazil’s poultry and swine industries.

To ensure a successful market entry, aXichem and Chr. Olesen are launching a PR campaign coinciding with the product’s debut. This campaign aims to educate and inform stakeholders across the spectrum, from industry professionals to regulatory bodies and consumers, about aXiphen’s benefits and its role in promoting safer, more sustainable animal production practices.

Gustavo Penz, Managing Partner, Feed Division Brazil at Chr. Olesen comments:

“We are enthusiastic about the synergy between our distribution efforts and the forthcoming PR campaign, designed to highlight aXiphen’s potential in revolutionizing Salmonella control. With the strategic timing of our launch at Nucleovet and the high-profile platform provided by SIAVS, we are confident that aXiphen will set a new standard in the industry.”

About Chr. Olesen

As a global distributor in the animal health and nutrition industry, Chr. Olesen is committed to delivering high-quality, safe, and sustainable solutions, contributing to the advancement of the animal production sector.

The information was submitted, through the care of the contact person below, for publication on
19 March 2024, at 13:00 CET.

Company contact:
Torsten Helsing, CEO, aXichem AB
Phone: +46 706 863 355 Email: [email protected]

About aXichem

aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company’s first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey; as an ingredient in food supplements for gut health, weight control and sports and exercise; and as an ingredient in food supplements for the bio- enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. Certified advisor for aXichem is Västra Hamnen Corporate Finance AB.

More information is available at www.axichem.com

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

View original content:https://www.prnewswire.com/news-releases/axichem-and-chr-olesen-set-to-revolutionize-brazils-poultry-and-swine-industries-with-axiphen-launch-at-nucleovet-and-siavs-302092939.html

SOURCE aXichem AB